Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$22.33 USD
-1.92 (-7.92%)
Updated Apr 17, 2024 09:49 AM ET
4-Sell of 5 4
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
HKMPF 22.33 -1.92(-7.92%)
Will HKMPF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HKMPF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for HKMPF
Collegium Pharmaceutical authorizes generic agreement with Hikma
U.K. Top 40 Quality Dividend Stocks: Q2 2024
Hikma price target raised to 2,000 GBp from 1,960 GBp at Berenberg
Hikma price target raised to 2,000 GBp from 1,850 GBp at Barclays
Hikma price target raised to 2,350 GBp from 2,200 GBp at JPMorgan